Abstract
Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Current Pharmaceutical Design
Title:Development of Peptide Vaccines in Dengue
Volume: 24 Issue: 11
Author(s): Kavita Reginald, Yanqi Chan, Magdalena Plebanski and Chit Laa Poh*
Affiliation:
- Research Centre for Biomedical Sciences, Sunway University, Bandar Sunway, Subang Jaya, Selangor,Malaysia
Keywords: Dengue, peptide vaccine, multi-epitope, synthetic peptides, HLA, cell mediated immunity.
Abstract: Dengue is one of the most important arboviral infections worldwide, infecting up to 390 million people and causing 25,000 deaths annually. Although a licensed dengue vaccine is available, it is not efficacious against dengue serotypes that infect people living in South East Asia, where dengue is an endemic disease. Hence, there is an urgent need to develop an efficient dengue vaccine for this region. Data from different clinical trials indicate that a successful dengue vaccine must elicit both neutralizing antibodies and cell mediated immunity. This can be achieved by designing a multi-epitope peptide vaccine comprising B, CD8+ and CD4+ T cell epitopes. As recognition of T cell epitopes are restricted by human leukocyte antigens (HLA), T cell epitopes which are able to recognize several major HLAs will be preferentially included in the vaccine design. While peptide vaccines are safe, biocompatible and cost-effective, it is poorly immunogenic. Strategies to improve its immunogenicity by the use of long peptides, adjuvants and nanoparticle delivery mechanisms are discussed.
Export Options
About this article
Cite this article as:
Reginald Kavita , Chan Yanqi , Plebanski Magdalena and Poh Laa Chit *, Development of Peptide Vaccines in Dengue, Current Pharmaceutical Design 2018; 24 (11) . https://dx.doi.org/10.2174/1381612823666170913163904
DOI https://dx.doi.org/10.2174/1381612823666170913163904 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Potential for Stem Cells Therapy in Alzheimer’s Disease: Do Neurotrophic Factors Play Critical Role?
Current Alzheimer Research Prebiotic Carbohydrates for Therapeutics
Endocrine, Metabolic & Immune Disorders - Drug Targets An Integrated Approach to Fragment-Based Lead Generation:Philosophy, Strategy and Case Studies from AstraZenecas Drug Discovery Programmes
Current Topics in Medicinal Chemistry Bradykinin Antagonists as Anti-Cancer Agents
Current Pharmaceutical Design Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Monoclonal Antibodies: A New Era in the Treatment of Non-Hodgkins Lymphoma
Current Pharmaceutical Biotechnology Can Probiotics Supplementation Improve Glycemic and Renal Status in Diabetic Nephropathy? A Systematic Review and Meta-Analysis of Clinical Trials
Endocrine, Metabolic & Immune Disorders - Drug Targets Amyloid Beta: The Alternate Hypothesis
Current Alzheimer Research Preclinical Assessment of Drug Combinations for the Treatment of Pain: Isobolographic and Dose-Addition Analysis of the Opioidergic System
CNS & Neurological Disorders - Drug Targets Influence of Polymer Molecular Weight on in-vitro Characteristics and Cytotoxicity of Fulvestrant Loaded Nanoparticles
Current Drug Therapy Current Drug Discovery for Anti-hepatitis C Virus Targeting NS4B
Current Topics in Medicinal Chemistry Preparation and Characterization of Mixed Polymeric Micelles as a Versatile Strategy for Meloxicam Oral Administration
Letters in Drug Design & Discovery Cytokine Modulation for Anti-Allergic Treatment
Current Pharmaceutical Design Brainstem Neuropeptides and Vagal Protection of the Gastric Mucosal Against Injury: Role of Prostaglandins, Nitric Oxide and Calcitonin-Gene Related Peptide in Capsaicin Afferents
Current Medicinal Chemistry Genetic and Epigenetic Signatures in Human Hepatocellular Carcinoma:A Systematic Review
Current Genomics Genetic and Pharmacological Modulation of Dendritic Cell-T Cell Interactions as a Therapeutic Strategy for Systemic Lupus Erythematosus
Current Gene Therapy Virus-Based RNA Silencing Agents and Virus-Derived Expression Vectors as Gene Therapy Vehicles
Recent Patents on Biotechnology Neutrophil Activation Induced by Plant Lectins: Modulation of Inflammatory Processes
Inflammation & Allergy - Drug Targets (Discontinued) Functional Role of Natural Antioxidants in Controlling Oxidative Stress Associated with SARS-CoV-2 Infection
Coronaviruses Association Between Chlamydia pneumoniae Antibodies and Lung Cancer: A Meta-Analysis
Current Respiratory Medicine Reviews